2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses an additional application of the LuCED test, a non-invasive tool used to detect early stage lung cancer.
Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses an additional application of the LuCED test, a non-invasive tool used to detect early stage lung cancer.
An additional application for the test is to detect dysplasia, states Zulueta. There is now evidence that chemo-prevention can be achieved in patients who have dysplasia.
This has been shown in phase II trials, explains Zulueta. Previously, in order to diagnose dysplasia there was an invasive test, however, now the LuCED test can provide a non-invasive diagnosis.
Related Content: